News
Zacks Investment Research on MSN13d
NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New IndicationIntellia Therapeutics NTLA announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation ...
Clinical Trials Arena on MSN5d
Intellia doses first subject in trial of nex-z for hereditary ATTRv-PNIntellia Therapeutics has commenced subject dosing in the Phase III MAGNITUDE-2 trial of nexiguran ziclumeran (nex-z) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback